genomic surveillance team identified the first 12 cases of the JN.1 lineage in Peru, a descendant of the highly-mutated BA.2.86 lineage (colloquially called 'Pirola') which comes from the
Through genomic surveillance of SARS-CoV-2, cases have been identified in respiratory samples taken between November 14 and 28 in Central Lima (7), Eastern Lima (2), Southern Lima (1), Callao (1), and San Martin region (1).
The cases involve people aged between 23-58 years old, who are currently stable and under outpatient management.
The INS researchers indicated that the JN.1 lineage was considered part of the BA.2.86 or 'Pirola' lineage.
However, given its rapid increase worldwide, and
currently being the second most prevalent lineage in the United States, the World Health Organization (WHO) decided on December 19, 2023, to classify the JN.1 lineage as a "variant of interest" separated from its parental lineage.
Just like BA.2.86, JN.1 is characterized by a large number of mutations, but has shown much more rapid dispersal.
This new variant of interest has already been detected in 43 countries, including the U.S., Canada, Mexico, and Brazil.
According to the evaluation carried out by the
WHO,
this variant is considered as "low risk" to public health.
Currently, there is no evidence that it causes a different or more severe medical condition compared to other Omicron lineages.
The vaccines continue to protect against severe disease and death from circulating SARS-CoV-2 variants, including JN.1, Minsa said.
As of epidemiological week 47, the XBB.1.5 (Kraken) variant still remains the most prevalent variant in Peru, accounting for 69% of cases.
The
Health Ministry underscores that these new lineages are detected as the outcome of genomic surveillance of SARS-CoV-2 carried out by the INS together with reference laboratories from various Peruvian regions.
Faced with the detection of this variant,
Minsa recommends strengthening COVID-19 control measures, especially completing the corresponding vaccination schedule, which includes the administration of the bivalent vaccine that offers specific protection against Omicron lineages such as JN.1.
In addition to vaccination, keeping rooms ventilated and wearing face masks in case of respiratory symptoms are recommended.